Literature DB >> 21216651

Effects of STN DBS for Parkinson's disease on restless legs syndrome and other sleep-related measures.

L M Chahine1, A Ahmed, Z Sun.   

Abstract

Restless legs syndrome (RLS) and other sleep abnormalities are common in Parkinson's Disease (PD). We prospectively examined sleep measures in PD patients undergoing subthalamic nucleus (STN) deep brain stimulation (DBS). An RLS questionnaire, Epworth Sleepiness Scale (ESS), and Parkinson's Disease Sleep Scale (PDSS) were administered through telephone interviews preoperatively and postoperatively. Seventeen patients were included. Mean preoperative and 4 weeks postoperative ESS scores were 11.6 and 6.4 respectively (p < 0.001) and PDSS scores were 94.2 and 122.9 respectively (p < 0.001). The improvement was sustained at 6 months. Six patients were diagnosed with RLS preoperatively. Mean preoperative International Restless Legs Syndrome Study Group rating scale score was 23.0. Mean 4 week and 6 month postoperative IRLSSG rating scale scores were 14.8 and 13.8 respectively, significantly improved compared to preoperative scores (p = 0.027 and p = 0.037 respectively). No patients developed new-onset RLS postoperatively. STN DBS improves daytime sleepiness, sleep quality, and RLS.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21216651     DOI: 10.1016/j.parkreldis.2010.11.017

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  35 in total

1.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

2.  Treatment options for sleep dysfunction in Parkinson's disease.

Authors:  Mary Ann Thenganatt; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

Review 3.  Therapies for Restless Legs in Parkinson's Disease.

Authors:  Valérie Cochen De Cock
Journal:  Curr Treat Options Neurol       Date:  2019-11-09       Impact factor: 3.598

4.  Vocalic transitions as markers of speech acoustic changes with STN-DBS in Parkinson's Disease.

Authors:  Vincent Martel-Sauvageau; Kris Tjaden
Journal:  J Commun Disord       Date:  2017-10-07       Impact factor: 2.288

5.  Effects of subthalamic nucleus deep brain stimulation on objective sleep outcomes in Parkinson's disease.

Authors:  Amy W Amara; Harrison C Walker; Allen Joop; Gary Cutter; Jennifer L DeWolfe; Susan M Harding; David G Standaert
Journal:  Mov Disord Clin Pract       Date:  2016-06-06

6.  Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease.

Authors:  Amy W Amara; David G Standaert; Stephanie Guthrie; Gary Cutter; Ray L Watts; Harrison C Walker
Journal:  Parkinsonism Relat Disord       Date:  2011-09-15       Impact factor: 4.891

7.  Automatic Sleep Stage Classification Based on Subthalamic Local Field Potentials.

Authors:  Yue Chen; Chen Gong; Hongwei Hao; Yi Guo; Shujun Xu; Yuhuan Zhang; Guoping Yin; Xin Cao; Anchao Yang; Fangang Meng; Jingying Ye; Hesheng Liu; Jianguo Zhang; Yanan Sui; Luming Li
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2019-01-01       Impact factor: 3.802

8.  Sleep dysfunction and its management in Parkinson's disease.

Authors:  Scott J Kutscher; Siavash Farshidpanah; Daniel O Claassen
Journal:  Curr Treat Options Neurol       Date:  2014-08       Impact factor: 3.598

9.  Linking restless legs syndrome with Parkinson's disease: clinical, imaging and genetic evidence.

Authors:  Tasneem Peeraully; Eng-King Tan
Journal:  Transl Neurodegener       Date:  2012-02-27       Impact factor: 8.014

Review 10.  Deep Brain Stimulation in Neurological and Psychiatric Disorders.

Authors:  Volker A Coenen; Florian Amtage; Jens Volkmann; Thomas E Schläpfer
Journal:  Dtsch Arztebl Int       Date:  2015-08-03       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.